范可尼贫血的移植治疗:来自巴西的经验教训
本文讨论在巴西库里蒂巴本中心为范可尼贫血患者建立造血干细胞移植项目的经验。由于国内无法进行体外T细胞去除,作者采用移植后环磷酰胺的单倍体移植平台以克服HLA不合移植相关的植入失败和GVHD,并描述了移植前环磷酰胺撤除及血清治疗加入等调整。
要点
- 匹配相关和无关供者HSCT后生存结局在过去二十年显著改善,即使在中低收入国家患者中亦然。
- 因体外T细胞去除不可用,本中心采用移植后环磷酰胺的单倍体移植平台以克服植入失败和GVHD。
- 撤除移植前环磷酰胺减轻了黏膜炎严重程度且未影响植入,加入血清治疗通过减少严重急慢性GVHD改善了总生存。
核心结论
- 匹配相关和无关供者HSCT后生存结局在过去二十年显著改善,但长期总生存仍因恶性肿瘤和其他疾病相关并发症风险而欠佳。
- 对于无良好匹配供者的患者,使用不全相合相关供者的替代供者移植是一种选择,但历史上与高植入失败和GVHD发生率相关。
- 本中心通过采用移植后环磷酰胺的单倍体移植平台、撤除移植前环磷酰胺及加入血清治疗,改善了总生存并扩大了HSCT可及性,但患者仍面临病毒再激活和GVHD等挑战。
- 作者承认在低资源环境下采用单倍体方法治疗范可尼贫血存在学习曲线,巴西经验可能需要进一步修改并与国家和国际合作才能在其它国家实施。
研究设计与样本
- 本文为单中心经验总结,讨论巴西库里蒂巴本中心为范可尼贫血患者建立HSCT项目的发展。
- 原文未报告样本量。
主要发现
- 匹配相关和无关供者HSCT后生存结局在过去二十年显著改善,即使在中低收入国家患者中亦然。
- 撤除移植前环磷酰胺减轻了黏膜炎严重程度且未影响植入。
- 加入血清治疗通过减少严重急性和慢性GVHD发生率改善了总生存。
- 患者仍面临病毒再激活和GVHD等挑战。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 本研究中心的做法是:因国内无法进行体外T细胞去除,采用移植后环磷酰胺的单倍体移植平台以克服HLA不合移植相关的植入失败和GVHD。
- 本研究中心的做法是:撤除移植前环磷酰胺以减轻黏膜炎严重程度。
- 本研究中心的做法是:加入血清治疗以减少严重急性和慢性GVHD发生率。
- 作者承认在低资源环境下采用单倍体方法存在学习曲线,巴西经验可能需要进一步修改并与国家和国际合作才能在其它国家实施。
局限性
- 作者承认在低资源环境下采用单倍体方法治疗范可尼贫血存在学习曲线。
- 巴西经验可能需要进一步修改并与国家和国际合作才能在其它国家实施。
- 患者仍面临病毒再激活和GVHD等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fanconi anaemia is a challenging disease to manage, and haematopoietic stem-cell transplantation (HSCT) is the treatment of choice for the haematological complications related to this disease. Over these past two decades, we have observed a substantial improvement in survival outcomes after matched related and unrelated donor HSCT, even for patients living in low-income and middle-income countries. Long-term overall survival is still suboptimal because of the risk of malignancies and other disease-related complications. For patients without well matched donors, alternative donor transplantation using mismatched related donors is an option but is historically associated with a high incidence of graft failure and graft-versus-host disease (GVHD). Herein we discuss the development of a HSCT programme for Fanconi anaemia in our centre in Curitiba, Brazil. Because ex vivo, T-cell depletion is unavailable in our country, we adapted the haploidentical donor transplantation platform using post-HSCT cyclophosphamide to overcome graft failure and GVHD associated with HLA-mismatched donor transplantation. The withdrawal of pre-HSCT cyclophosphamide reduced the severity of mucositis and did not interfere with engraftment. The addition of serotherapy improved overall survival by decreasing the incidence of severe acute and chronic GVHD. Although we have improved overall survival and expanded access to HSCT for Fanconi anaemia, our patients face many challenges, especially viral reactivation and GVHD disease, that merit attention. We acknowledge that there is a learning curve to adopt the haploidentical approach for Fanconi anaemia to low-resourced settings, and this Brazilian experience might require further modifications along with national and international collaborations to be implemented in other countries.
引用
- Bonfim C, Nichele S, Loth G, et al. Transplantation for Fanconi anaemia: lessons learned from Brazil. Lancet Haematol. 2022. PMID: 35240077. doi:10.1016/S2352-3026(22)00032-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。